LuMind IDSC statement on FDA approval of Leqembi

leqembi

LuMind IDSC issues statement following FDA full approval of Leqembi™ to treat early-stage Alzheimer’s disease  July 7, 2023 In a groundbreaking decision that signals new hope for people with Alzheimer’s […]

LuMind IDSC Statement re: Donanemab Phase 3 Results

Brain research

Pharmaceutical company Eli Lilly today announced results of a phase III clinical trial that proves their anti-amyloid drug, donanemab, significantly slowed cognitive and functional decline in people with early symptomatic […]

New Year Greetings from Hampus Hillerstrom

Oskar and Hampus cropped

Dear Friend of LuMind IDSC, Recently, I spoke with a family whose newborn baby had heart surgery. As many of you who have been through similar experiences can attest to, […]